miR-381-3p participates in chondrogenesis and cartilage degradation by alleviating collagen 2 expression and enhancing mmp13 expression  by Hou, C. et al.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S320Results: Chips data analysis demonstrated not only that 15 miRNAs
varied signiﬁcantly during MSC proliferation and preconditionning but
also that 17 MSC miRNA varied signiﬁcantly during chondrogenic 3D
differentiation. By quantitative PCR, we conﬁrmed that miR-29b
expression level was signiﬁcantly down-regulated by PAD supplement
at passage 3 stage during hMCS monolayer expansion. On one hand,
during 3D differentiation we conﬁrmed by qPCR miR-29b down-regu-
lation until Day 14. On the other hand, miR-140 expressionwas strongly
signiﬁcantly increased throughout the chondrogenic differentiation.
MSC chondrogenic differentiation was conﬁrmed at the gene (COLA21,
ACAN, SOX9) and tissue levels: type II collagen was present in extrac-
ellular matrix (immunohistochemistry) as proteoglycans (Alcian blue
staining).
Conclusions: As miR-29b is known for its anti-proliferative properties
under certain conditions, its inhibition/repression may favour cell
proliferation and matrix synthesis. Besides, miR-140 is one of a very
limited number of noncoding microRNAs (miRNAs) mainly expressed in
cartilage. Our results conﬁrm that miR-140 increases during MSC driven
chondrogenesis. Finally, miR29 repression and mir140 induction likely
play a role in MSC-driven cartilage engineering and may have value as
biomarkers and/or therapeutic target.
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METHODS FOR THE IDENTIFICATION OF MICRORNA-455 TARGETS
T.E. Swingler y, L. Le y, H. Pais y, M.J. Barter z, D.A. Young z, T. Dalmay y,
I.M. Clark y. yUniv. of East Anglia, Norwich, United Kingdom; zNewcastle
Univ., Newcastle-upon-Tyne, United Kingdom
Purpose: MicroRNAs (miRNAs) have emerged as a new class of gene
expression regulators that are important in both normal cartilage
physiology and pathology. We have previously identiﬁed several
microRNAs that are regulated in osteoarthritis, including microRNA-
455, a key Sox9-responsive microRNA. MiRNAs are 20-24 nucleotide
non-coding RNA molecules that post-transcriptionally regulate gene
expression. MicroRNAs are known to simultaneously target many
transcripts, possibly to ﬁne tune complex signalling pathways. A single
miRNA can regulate multiple mRNAs via binding to sequences in the
3’UTR either promoting mRNA decay or repressing translation. mRNA
proﬁling can be used to identify some miRNA targets, but fails to
identify targets that change only at the protein level and to distinguish
direct from indirect targets. We have over-expressed or inhibited miR-
455-3p and performed whole genome arrays to identify genes that are
regulated at the mRNA level. By combining the analysis of whole
genome array data and the analysis of the promoter sequences of
regulated genes, the purpose of this study was to identify both targets
that are regulated at the mRNA or only at the protein level.
Methods: Primary chondrocytes were transfected with either 50nM
miR-455-3p mimic or inhibitor or non-targeting controls. Cells were
incubated for 48 hours and harvested for mRNA using Trizol (Invi-
trogen). Illumina whole genome micro-array analysis was performed to
identify genes regulated at the mRNA level. We further analysed the
3’UTR sequence of regulated genes for mir-455-3p binding sites using
the software package R. We also used pathway analysis to identify
groups of functionally related genes. To identify genes that change only
at the protein level, the promoter sequences (2000nt downstream of
the transcriptional start site) of all regulated genes were downloaded
from Ensembl (www.Ensembl.org) and analysed for all 6mer binding
motifs (AAAAAA, AAAAAT, etc 4^6 ¼ 4096 motif sequences) using the
software package R. To analyse putative targets of miR-455-3p the 3’
UTRs of potential targets were subcloned downstream of a luciferase
gene for experimental validation.
Results: Following the over-expression or inhibition of miR-455-3p, we
have generatedmRNA expression proﬁles that have identiﬁed a number
of genes regulated at the mRNA level or protein level. Genes where the
mRNA was both decreased by over-expression of miR-455-3p and
increased by its inhibition, and contain a miR-455-3p-binding site,
include members of the WNT signalling pathway including DKK1, beta-
catenin, and GSK. Following analysis of the promoter sequences of
regulated mRNA, two motifs were identiﬁed, CACGTG and CAGGTG
which are binding sites for the transcription factor TCF3, itself impli-
cated in WNT signalling. Luciferase assays conﬁrmed TCF3 as a direct
target of miR-455-3p.
Conclusions: We have combined different bioinformatic analyses of
mRNA datasets to identify direct targets of miR-455-3p which change at
the mRNA level or only at the protein level. Pathway analysis has alsorevealed that miR-455 may regulate multiple points in the WNT sig-
nalling pathway.
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miRNA EXPRESSION PROFILE IN MESENCHYMAL STEM CELLS FROM
OA PATIENTS DURING OSTEOGENIC DIFFERENTIATION
P. Tornero-Esteban, J. Lamas, L. Rodriguez-Rodriguez, E. Villafuertes,
J. Hoyas, F. Marco, B. Fernandez-Gutierrez. Hosp. Clinico San Carlos,
Madrid, Spain
Purpose: Osteoarthritis (OA) is a common and disabling muscu-
loskeletal disorder. The most evident feature of OA is articular cartilage
loss however changes in bone also occur, including increased volume
and reduced mineralization. Homeostasis of bone tissue largely relies
on the ability of self-renewal and differentiation of precursor mesen-
chymal stem cells (MSCs) driven by the activity of signalling pathways
such as the Wnt, MAPK, TGF-b and Hedgehog. These set of cellular
processes interact and integrate the signals in a highly regulated
manner in which miRNAs can play a critical role. miRNAs act silencing
the expression of different genes at the translational level and therefore
can interfere through the activation or inhibition of essential processes
involved in cell fate commitment.
The main objective of this work was to identify comparatively the
miRNA expression proﬁle occurring during MSCs osteogenic differ-
entiation in vitro in MSCs isolated from OA patients and healthy sub-
jects to decipher their possible relevance in OA pathology.
Methods:MSCs isolated from the bone marrow of 5 OA (OA-MSCs) and
3 healthy individuals (H-MSCs) with similar ages were isolated, char-
acterised and further induced to osteogenic differentiation at the sixth
passage. mRNAwas collected at different time points: 0, 10 and 21 days.
The miRNA pool was isolated and the expression proﬁle of 754 well-
characterized miRNA sequences from the Sanger miRBase v14 were
obtained using the TaqMan OpenArray Human miRNA Panel,
according to the manufacturer instructions. Raw data was analyzed
using generalized lineal models. The potential role of the differentially
expressed miRNAs was assessed using the predicted targets provided in
the mirTar database.
Results: Expression proﬁling during osteogenic differentiation revealed
at t¼0 the differential expression of 3 miRNAs: miR-320; miR-616 and
miR-99b (p¼0.002) in undifferentiated OA-MSCs compared with H-
MSCs. miR-320 and miR-99b, initially downregulated In OA-MSCs,
showed a progressive increase at t¼10 and t¼21 during differentiation
process. Conversely, expression levels of miR-616, initially upregulated
in OA-MSCs, progressively decrease during differentiation process.
Although no signiﬁcant differences were found, the opposite trend was
observed for H-MSCs. The functional pathway analysis for the differ-
entially expressed miRNAs showed that several of their predicted or
validated target genes were involved in signalling pathways essentials
for the maintenance of bone homeostasis, these include several pro-
teins of the Wnt, MAPK, TGFb and Hedgehog signalling pathways.
Conclusions: Bone homeostasis alterations are one of the features
characterising OA pathology. Here we have described that miR-320;
miR-616 and hsa-miR-99b likely involved in the modulation of crucial
signalling pathways for MSCs osteogenic commitment. To our knowl-
edge none of them have been described previously in this biological
context. Although further validation of results is required to deﬁne their
particular or jointly contribution, these preliminary results suggest
their role in OA pathophysiology. A more complete understanding of
these differential expressedmiRNA regulatory functions is likely to shed
light on the molecular mechanism dysregulated in OA an thus could be
useful for the development of novel therapeutic approaches.
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MIR-381-3P PARTICIPATES IN CHONDROGENESIS AND CARTILAGE
DEGRADATION BY ALLEVIATING COLLAGEN 2 EXPRESSION AND
ENHANCING MMP13 EXPRESSION
C. Hou, Z. Zhang, Z. Yang, P. Wu, M. Gu, W. Liao. First afﬂiated Hosp. of
Sun Yat-Sen Univ., Guangzhou, China
Purpose: To investigate the biological effect of mmu-miR-381-3p on
chondrogenic differentiation and interleukin-1beta (IL-1b) induced
arthritis model.
Methods: Chondrocyte-like ATDC5 cell line was stimulated with ITSþ
premix to form cartilage nodules. Total RNA was isolated and reverse
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S321transcripted into cDNA. The mmu-miR-381-3p mimic/inhibitor were
transfected into cells with lipofectamine 2000. The miR-381-3p in
mouse embryo and degraded cartilage was stained with insitu
hybridization method.
Results: The miR-381 expression was elevated in chondrogenic ATDC5.
The in situ hybridization assay identiﬁed the presence of miR-381 in
degraded cartilage of osteoarthritis patients and in enchondral bone
formating claws of mouse embryo.
The miR-381 obviously suppressed the collagen 2 expression and
enhanced mmp13 expression.
Conclusions: The miR-381 may participate in chondrogenesis and
cartilage degradation by alleviating collagen 2 expression and
enhancing mmp13 expression.Nutraceuticals/ Dietary Supplements and OA
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SHELLS FROM ROSE-HIP (ROSA CANINA) DO NOT REDUCE SYMPTOM
SCORES OR IMPROVE ANTI-INFLAMMATORY PROPERTY IN PATIENTS
WITH OSTEOARTHRITIS – A DOUBLE-BLIND, PLACEBO-CONTROLLED,
RANDOMIZED STUDY
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: Placebo controlled studies on a standardised rose-hip powder,
Hyben-Vital, based on daily intake of 2.5 g seeds and 2.5 g shells,
indicate alleviation of symptoms from osteoarthritis. The same powder
also shows anti-inﬂammatory properties, by lowering C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate. On the latest OARSI
meeting, data from a partly blinded, exploratory study, on rose-hip
powder, based exclusively on shells, was presented. The study, which
did not include placebo or measurements of inﬂammatory markers,
suggested that the shell powder (2.25 g daily) could have equal, orperhaps stronger effect, than the double dose of said shell powder (4.5 g
daily), or even the original Hyben-Vital powder (5 g daily) containing
50% shells and 50% seeds. An inverse dose-response curve, where less
powder gives higher response, was introduced in the study. The
inclusion of a placebo arm would have made the study even stronger.
The present study, therefore, aims to test whether this low-dose shell
powder shows any impact on symptoms of OA and/or reduction in CRP,
when tested against placebo treatment.
Methods: Ninety-four patients, a sub fraction from a study on the
occurrence of common cold during the winter season (ClinicalTrials.gov
Identiﬁer NCT 01459952), all diagnosed with OA according to the cri-
teria of the American College of Rheumatology, participated in the
present study. Forty-seven patients received 90% rosehip shells and 10%
rose hip seeds in total (2.20 gram daily) and the remaining forty-seven
patients received placebo of similar taste and colour. All patients were
followed for 6 months. Pain and stiffness was estimated on a numerical
scale from 0-10 (more symptom - higher score) and patient’s global
assessment of disease severity (PGAD)was estimated on a 100mm scale
(WOMAC). Quality of life was estimated using SF-12, and CRP by normal
laboratory routine. The Wilcoxon tested within groups and the Man-
Whitney was used when comparing groups. A p-value less than 0.050
was regarded as statistically signiﬁcant. All data given is on the inten-
tion to treat basis. To further test if an impact from active treatment, if
present, was based on treatment it self or was possibly random - a dose
dependency tests - wasmade on both groups by testing for a correlation
between patient weight and symptom score.
Results: Pain declined as a result of active treatment from 4.72 þ/- 2.41
to 3.44 þ/- 2.19 (p<0.050). Placebo resulted in similar results: 4.91 þ/-
3.07 declined to 3.99 þ/-2.74, p<0.086. Man-Whitney p value <0.880.
Stiffness likewise declined in both groups. Active treatment: 3.57 þ/-
2.38 declined to 2.95 þ/- 1.88 (p<0.236) and placebo: 4.50 þ/- 2.93
declined to 3.80 þ/- 2.85, (p<0.033). Man-Whitney p value: 0.274. No
signiﬁcant change was observed in PGAD: active treatment 31.0 þ/-21
changing to 33.0 þ/-20.0 (p<0.527) and placebo 42.0 þ/-27 unchanged
42.0 þ/-24.0 (p<0.541). Mann-Whitney p-value 0.520. Quality of life
(SF-12 physical and SF-12 psychological) did not show any changes
(data not given). CRP remained unchanged during both treatments,
Mann-Whitney p-value: 0.347. There was no correlation between
patient weight and the change in symptom scores in either of the two
groups at any time point of the study (data not given). This demon-
strates a lack of effect of shell powder treatment. The lighter patient at
60 kg had the same lack of effect as had the heavier patient at 110 kg.
Conclusions: In regards to impact on symptom scores of OA, quality of
life and reduction in CRP, low-dose rose-hip powder based mainly on
shells, is comparable to placebo. The effect in symptom scores of OA,
quality of life and reduction in CRP seen in previous studies on stand-
ardised rose-hip powder from Rosa canina may be highly dependent on
the higher content of seeds.
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LOW-DOSE SEED AND SHELL POWDER FROM ROSE-HIP (ROSA
CANINA) CAN ALEVIATE SYMPTOMS OF OSTEOARTHRITIS AND
REDUCE C-REACTIVE PROTEIN IN PATIENTS SUFFERING FROM
OSTEOARTHRITIS
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: A meta-analysis has shown that a standardised rose-hip
powder, Hyben-Vital containing seeds and shells from Rosa canina,
reduces symptoms of osteoarthritis (OA), when used in the dose of 5 g
daily. The same remedy can also reduce markers of inﬂammation. The
aim of the present study was to test if the aforementioned rose-hip
powder, when given as a booster of 5 grams daily for 3 weeks, then
followed by 2.5 g for the following 9 weeks, would alleviate symptoms
of osteoarthritis and reduce C-reactive protein (CRP) in patients suf-
fering from OA of the hip or knee.
Methods: The study (ClinicalTrials.gov Identiﬁer NCT01459939) inclu-
ded 120 patients who were allocated randomly to either active treat-
ment: 5 grams daily for the ﬁrst 3 weeks followed by 2.5 gram daily for
the following 9 weeks, or placebo in a similar dose and of similar colour,
taste and smell. All the patients were diagnosed with OA according to
the criteria of the American College of Rheumatology. The WOMAC
questionnaire was used throughout. The primary effect variables were
pain and activity of daily living (ADL). A Secondary effect variable was
stiffness. CRP was estimated using normal laboratory routine. The
